Progress of minimal residual disease monitoring in adult acute lymphoblastic leukemia
10.3760/cma.j.cn115356-20220325-00088
- VernacularTitle:微小残留病监测在成年人急性淋巴细胞白血病中的研究进展
- Author:
Zhihuan YANG
1
;
Ying WANG
Author Information
1. 中国医学科学院血液病医院（中国医学科学院血液学研究所） 实验血液学国家重点实验室 国家血液系统疾病临床医学研究中心 细胞生态海河实验室 天津市血液病细胞治疗研究重点实验室，天津 300020
- Keywords:
Leukemia, lymphocytic, acute;
Minimal residual disease;
Chimeric antigen receptor T-cell;
Blinatumomab;
Treatment
- From:
Journal of Leukemia & Lymphoma
2023;32(5):310-313
- CountryChina
- Language:Chinese
-
Abstract:
Acute lymphoblastic leukemia (ALL) is a malignancy originating from B-/T-lineage lymphoid progenitor cells. With the continuous development of new drugs as well as therapeutic regimens, adult ALL patients have improved complete remission rates and overall survival rates, but the survival rate of patients after relapse remains low. The positive minimal residual disease after complete remission is an important reason for relapse. Although minimal residual disease monitoring has been found to be important in predicting patients prognosis in recent years, the uniform stratified treatment protocols have not yet been developed in the clinical practice of adult ALL. This article reviews the prognostic significance of minimal residual disease monitoring at different time points, as well as the progress of removal methods of minimal residual disease.
